Chronomodulated chemotherapy: clinical value and possibilities for dissemination in the United States

REFERENCES

• Wood P.A., Hrushesky W.J. Circadian rhythms and cancer chemotherapy. Critical Reviews in Eukaryotic Gene Expression 1996; 6(4)299–343
   PubMedGoogle Scholar
• Mormont M.C., Lévi F. Circadian-system alterations during cancer processes: a review. International Journal of Cancer 1997; 70(2)241–247
   PubMed Web of Science ®Google Scholar
• Wood P.A., Hrushesky W.J. Biological perspectives on circadian cancer therapy. Journal of Infusional Chemotherapy 1995; 5(4)182–190
   PubMedGoogle Scholar
• Lévi F. Cancer chronotherapy. Journal of Pharmacy and Pharmacology 1999; 51(8)891–898
   PubMedGoogle Scholar
• Lévi F. Therapeutic implications of circadian rhythms in cancer patients. Novartis Foundation Symposium 2000; 227: 119–136
   PubMedGoogle Scholar
• Cornelissen G., Gubin D., Halberg F., Milano G., Halberg F. Chronomedical aspects of oncology and geriatrics. In Vivo 1999; 13(1)77–82
   PubMedGoogle Scholar
• Giacchetti S., Itzhaki M., Gruia G., Adam R., Zidani R., Kunstlinger F., Brienza S., Alafaci E., Bertheault-Cvitkovic F., Jasmin C., Reynes M., Bismuth H., Misset J.L., Lévi F. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Annals of Oncology 1999; 10(6)663–669
   PubMed Web of Science ®Google Scholar
• Focan C., Lévi F., Kreutz F., Focan-Henrard D., Lobelle J.P., Adam R., Dallemagne B., Jehaes C., Markiewicz S., Weerts J., Bismuth H., Jasmin C., Misset J.L. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. Anti-Cancer Drugs 1999; 10(4)385–392
   PubMedGoogle Scholar
• Focan C., Kreutz F., Focan-Henrard D., Moeneclaey N. Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial. European Journal of Cancer 2000; 36(3)341–347
   PubMedGoogle Scholar
• Lévi F., Zidani R., Brienza S., Dogliotti L., Perpoint B., Rotarski M., Letourneau Y., Llory J.F., Chollet P., Le Rol A., Focan C. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 1999; 85(12)2532–2540
   PubMedGoogle Scholar
• de Gramont A., Louvet C., Andre T., Tournigand C., Krulik M. A Review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a Regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). European Journal of Cancer 1998; 34(5)619–626
   PubMed Web of Science ®Google Scholar
• Kohne C.H., Wilke H., Schoffski P., Schmoll H.J. The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer. Journal of Infusional Chemotherapy 1996; 6(4)206–210
   PubMedGoogle Scholar
• Poorter R.L., Bakker P.J., Veenhof C.H. Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine. Pharmacy World and Science 1998; 20(2)45–59
   PubMedGoogle Scholar
• de Gramont A., Louvet C., Krulik M. The French experience with infusional 5-fluorouracil in advanced colorectal cancer. Journal of Infusional Chemotherapy 1996; 6(3)133–136
   PubMedGoogle Scholar
• Lévi F. Chronotherapy for gastrointestinal cancers. Current Opinion in Oncology 1996; 8(4)334–341
   PubMedGoogle Scholar
• Gorins A. Quality of life. European Journal of Gynaecological Oncology 1996; 17(1)5–6
   PubMedGoogle Scholar
• Physicians urged to address quality of life after breast cancer treatment. Oncology 1995; 9(11)1123–1124
   Google Scholar
• Coates A., Gebski V. On the receiving end. VI. Which dimensions of quality-of-life scores carry prognostic information?. Cancer Treatment Reviews 1996; 22(Suppl. A)63–67
   PubMedGoogle Scholar
• Swain S.M., Rowland J., Weinfurt K., Berg C., Lippman M.E., Walton L., Egan E., King D., Spertus I., Honig S.F. Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. Journal of Clinical Oncology 1996; 14(5)1565–1572
   PubMedGoogle Scholar
• Hurny C., Bernhard J., Coates A.S., Castiglione-Gertsch M., Peterson H.F., Gelber R.D., Forbes J.F., Rudenstam C.M., Simoncini E., Crivellari D., Goldhirsch A., Senn H.J. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 1996; 347(9011)1279–1284
   PubMedGoogle Scholar
• Carlson R.W., Sikic B.I. Continuous infusion or bolus injection in cancer chemotherapy. Annals of Internal Medicine 1983; 99(6)823–833
   PubMedGoogle Scholar
• Vogelzang N.J. Continuous infusion chemotherapy: a critical review. Journal of Clinical Oncology 1984; 2(11)1289–1304
   PubMed Web of Science ®Google Scholar
• Bukowski R.M. The need for cytoprotection. European Journal of Cancer 1996; 32A(Suppl. 4)S2–S4
   Google Scholar
• Uma Devi P. Normal tissue protection in cancer therapy—progress and prospects. Acta Oncologica 1998; 37(3)247–252
   PubMedGoogle Scholar
• Viele C.S., Holmes B.C. Amifostine: drug profile and nursing implications of the first pancytoprotectant. Oncology Nursing Forum 1998; 25(3)515–523
   PubMedGoogle Scholar
• Schuchter L.M. Current role of protective agents in cancer treatment. Oncology 1997; 11(4)505–512
   PubMedGoogle Scholar
• Schuchter L.M. Current role of protective agents in cancer treatment. Oncology 1997; 11(4)505–512
   PubMedGoogle Scholar
• Lupulescu A.P. Hormones, vitamins, and growth factors in cancer treatment and prevention. A critical appraisal. Cancer 1996; 78: 2264–2280
   PubMed Web of Science ®Google Scholar
• Valstar E. Nutrition and cancer: a review of the preventive and therapeutic abilities of single nutrients. Journal of Nutrition and Medicine 1994; 4: 79–198
   Google Scholar
• Block K.I. Dietary impact on quality and quantity of life in cancer patients. Adjuvant Nutrition in Cancer Treatment, P. Quillin, R.M. Williams. Cancer Treatment Research Foundation/American College of Nutrition, Arlington Heights, IL 1993; 99–127
   Google Scholar
• Heber D., Blackburn G.L., Vay Liang W.G. Introduction: the principles of nutritional oncology. Nutritional Oncology, D. Heber, G.L. Blackburn, W.G. Vay Liang, J.F. Holland. Academic Press, San Diego 1999; 1–4
   Google Scholar
• Block K.I. Nutritional oncology and complementary medicine. Essentials of Complementary and Alternative Medicine, W.B. Jonas, J.S. Levin. Lippincott, Williams and Wilkins, Baltimore, MD 1999
   Google Scholar
• Hospers G.A., Eisenhauer E.A., de Vries E.G. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. British Journal of Cancer 1999; 80(5–6)629–638
   PubMed Web of Science ®Google Scholar
• Oates K.K., Schulof R.S., Goldstein A.L., Sztein M.B. Cancer-associated immune suppression: therapeutic alterations with chemical and biological agents. Principles of Cancer Biotherapy, Robert K. Oldham. 2nd ed., Marcel Dekker, Inc., New York 1991; 150
   Google Scholar
• Thiruvengadam R., Kaneshiro C., Iyer P., Slater L., Kurosaki T. Effect of antioxidant vitamins and mineral on chemotherapy-induced cytopenia. Proceedings of ASCO 1996; 15: 550
   Google Scholar
• Clemens M.R., Muller-Ladner C.I., Gey K.F. Vitamins during high dose chemo- and radiotherapy. Zeitschrift fur Ernahrungswissenschaft 1992; 31(2)110–120
   PubMedGoogle Scholar
• Furst P., Albers S., Stehle P. Evidence for a nutritional need for glutamine in catabolic patients. Kidney International. Supplement 1989; 27((HD))S287–S292
   Google Scholar
• Miller A.L. Therapeutic considerations of l-glutamine: a review of the literature. Alternative Medicine Review 1999; 4(4)239–248
   PubMedGoogle Scholar
• Klimberg V.S., McClellan J.L. Glutamine, cancer, and its therapy. American Journal of Surgery 1996; 172(5)418–424
   PubMedGoogle Scholar
• MacBurney M., Young L.S., Ziegler T.R., Wilmore D.W. A cost-evaluation of glutamine-supplemented parenteral nutrition in adult bone marrow transplant patients. Journal of the American Dietetic Association 1994; 94(11)1263–1266
   PubMedGoogle Scholar
• Earle C.C., Venditti L.N., Neumann P.J., Gelber R.D., Weinstein M.C., Potosky A.L., Weeks J.C. Who gets chemotherapy for metastatic lung cancer?. Chest 2000; 117(5)1239–1246
   PubMedGoogle Scholar
• Guidry J.J., Greisinger A., Aday L.A., Winn R.J., Vernon S., Throckmorton T.A. Barriers to cancer treatment: a review of published research. Oncology Nursing Forum 1996; 23(9)1393–1398
   PubMedGoogle Scholar
• Mellette S.J. The cancer patient at work. CA: A Cancer Journal for Clinicians 1985; 35(6)360–373
   PubMedGoogle Scholar
• Moore K.A. Breast cancer patients' out-of-pocket expenses. Cancer Nursing 1999; 22(5)389–396
   PubMedGoogle Scholar
• Ayanian J.Z., Guadagnoli E. Variations in breast cancer treatment by patient and provider characteristics. Breast Cancer Research and Treatment 1996; 40(1)65–74
   PubMedGoogle Scholar
• Greenberg E.R., Chute C.G., Stukel T., Baron J.A., Freeman D.H., Yates J., Korson R. Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. New England Journal of Medicine 1988; 318(10)612–617
   PubMed Web of Science ®Google Scholar
• Joranson D.E. Are health-care reimbursement policies a barrier to acute and cancer pain management?. Journal of Pain and Symptom Management 1994; 9(4)244–253
   PubMedGoogle Scholar
• Knusli C., Obrecht J.P. Cost aspects of oncologic chemotherapy. Schweizerische Rundschau fur Medizin Praxis 1989; 78(18)515–519
   PubMedGoogle Scholar
• Jagannath S., Vesole D.H., Zhang M., Desikan K.R., Copeland N., Jagannath M., Bracy D., Jones R., Crowley J., Tricot G., Barlogie B. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplantation 1997; 20(6)445–450
   PubMedGoogle Scholar
• Penberthy L., Retchin S.M., McDonald M.K., McClish D.K., Desch C.E., Riley G.F., Smith T.J., Hillner B.E., Newschaffer C.J. Predictors of medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer. Health Care Management Science 1999; 2(3)149–160
   PubMedGoogle Scholar
• Hrushesky W.J. Cancer chronotherapy: a drug delivery challenge. Progress in Clinical and Biological Research 1990; 341A: 1–10
   PubMedGoogle Scholar
• Takeshita A., Sakamaki H., Miyawaki S., Kobayashi T., Kuriyama K., Yamada O., Oh H., Takenaka T., Asou N., Ohno R. Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group. Cancer 1995; 76(4)602–608
   PubMedGoogle Scholar